Why the study?
Does finerenone reduce NT-proBNP levels and clinical events compared to eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease?
Does finerenone reduce NT-proBNP levels and clinical events compared to eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease?
Finerenone is well tolerated and similarly effective to eplerenone in reducing NT-proBNP in patients with worsening chronic heart failure and diabetes or CKD.
Answers are grounded in this paper and cite their sources.
Finerenone matches eplerenone on NT-proBNP reduction and tolerability in worsening HF; leaves open clinical event reduction pending dedicated outcomes trials.
Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone. The finding of reduced clinical events in the finerenone 10→20 mg group should be further explored in a large outcomes trial.
No takes yet. Share an insight, caveat, or question.
Filippatos et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: